[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-344830-105":59,"doc-detail-344830-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","magnetic-resonance-guided-simultaneous-multi-focal-adaptive-radiotherapy-for-prostate-pelvis-metastases-mrgsmart-pem-in-prostate-cancer-a-prospective-phase-ii-study","Magnetic resonance-guided simultaneous multi-focal adaptive radiotherapy for prostate, pElvis & metastases (MRgSMART-PEM) in prostate cancer - a prospective phase II study","","Purpose To evaluate safety, feasibility, and patient-reported outcomes of magnetic resonance-guided simultaneous multi-focal adaptive radiotherapy for the prostate, pelvis, and metastases (MRgSMART-PEM) in high-risk, very-high-risk, or oligometastatic prostate cancer. Methods and materials A prospective single-arm phase II study treated 35 pathologically confirmed patients with MRgSMART-PEM on a 1.5-T MR-Linac using an Adapt-to-Shape workflow. Primary endpoint was acute grade ≥2 GU and GI toxicity within 12 weeks; secondary endpoints included late toxicity, quality of life, and survival outcomes. Results Median follow-up was 17.2 months; acute grade ≥2 GU and GI toxicities occurred in 5.7% each, with all resolving within 8 weeks; QoL returned to baseline by 3 months. Conclusions MRgSMART-PEM was feasible, safe, and well tolerated with excellent local control and minimal toxicity.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/magnetic-resonance-guided-simultaneous-multi-focal-adaptive-radiotherapy-for-prostate-pelvis-metastases-mrgsmart-pem-in-prostate-cancer-a-prospective-phase-ii-study/344830/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/magnetic-resonance-guided-simultaneous-multi-focal-adaptive-radiotherapy-for-prostate-pelvis-metastases-mrgsmart-pem-in-prostate-cancer-a-prospective-phase-ii-study/344830.png","ImageObject",300,407,{"name":92,"@type":93},"Lucas Martin","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main purpose of MRgSMART-PEM in this study?","Question",{"text":112,"@type":113},"To evaluate the safety, feasibility, and patient-reported outcomes of magnetic resonance-guided simultaneous multi-focal adaptive radiotherapy for the prostate, pelvis, and metastases in specific high-risk categories of prostate cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the radiotherapy delivered and what was the study design?",{"text":117,"@type":113},"This was a prospective single-arm phase II study. Thirty-five patients were treated with MRgSMART-PEM on a 1.5-T MR-Linac between June 2021 and March 2025, delivered in five alternate-day fractions using an Adapt-to-Shape workflow.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key toxicity and quality-of-life findings?",{"text":121,"@type":113},"Acute grade ≥2 GU and GI toxicities occurred in 5.7% of patients each, and all resolved within 8 weeks. No late grade ≥2 toxicities were observed, and quality-of-life scores declined at 2 weeks but returned to baseline by 3 months.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},344830,1790442456,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Sun et al. Radiation Oncology (2026) 21:37 [https://doi.org/10.1186/s13014-026-02799-9](https://doi.org/10.1186/s13014-026-02799-9)  \nRadiation Oncology  \nRESEARCH Open Access  \nMagnetic resonance-guided simultaneous multi-focal adaptive radiotherapy for prostate, pElvis & metastases (MRgSMART-PEM) in prostate cancer: a prospective phase II study  \nMeng Sun1†, Shi-Rui Qin1†, Ran Wei1†, Yuan Tian1, Ling-Ling Yan1, Wen-Long Xia1, Zhi-Qiang Liu1, Qi Fu 1, Yong-Wen Song1, Hui Fang1, Hao Jing1, Shu-Lian Wang1, Ye-Xiong Li1, Nian-Zeng Xing2* and Ning-Ning Lu 1,3*  \nAbstract  \nPurpose To evaluate the safety, feasibility, and patient-reported outcomes of magnetic resonance-guided simultaneous multi-focal adaptive radiotherapy for the prostate, pelvis, and metastases (MRgSMART-PEM) in patients with high-risk, very-high-risk, or oligometastatic prostate cancer.  \nMethods and materials In this prospective single-arm phase II study, 35 patients with pathologically confirmed prostate cancer (11 localized, 8 pelvic nodal, 16 oligometastatic) were treated with MRgSMART-PEM on a 1. 5-T MR-Linac between June 2021 and March 2025. Radiotherapy was delivered in five alternate-day fractions using an Adapt-to-Shape workflow. The primary endpoint was clinician-reported acute grade ≥ 2 genitourinary (GU) and gastrointestinal (GI) toxicity within 12 weeks. Secondary endpoints included late toxicity, quality of life (QoL), and survival outcomes.  \nResults Median follow-up was 17.2 months (range, 4 .3–49. 3) . The median on-couch time was 59 min (range, 35–80) . Acute grade ≥ 2 GU and GI toxicities occurred in 5 . 7% of patients each, including one grade 3 GI event; all resolved within 8 weeks. No late grade ≥ 2 toxicities were observed, and no grade 1 events persisted beyond 18 months. QoL scores declined at 2 weeks post-treatment but returned to baseline by 3 months. At 2 years, biochemical and clinical progression-free survival rates were both 87.4%, and in-field control was 100% .  \n†Meng Sun, Shi-Rui Qin and Ran Wei contributed equally to this study and shared first authorship.  \n*Correspondence:  \nNian-Zeng Xing [xingnianzeng@126.com](xingnianzeng@126.com)[ ](xingnianzeng@126.com)Ning-Ning Lu [Ning-Ning.Lu@hotmail.com](Ning-Ning.Lu@hotmail.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nSun et al. Radiation Oncology (2026) 21:37 Page 2 of 11  \nConclusions MRgSMART-PEM is feasible, safe, and well tolerated in patients with high-risk, very-high-risk, andoligometastatic prostate cancer, achieving excellent local control with minimal toxicity and recovery of QoL. These results support further evaluation of MRgSMART-PEM in randomized trials.  \nTrial registration NCT05183074 (Chinese Academy of Medical Sciences, First Posted 2022-01-10) .  \nKeywords Prostate cancer, Oligo-metastases, Adaptive radio","cbCaidP4vNfPW3oc","https://ap.wps.com/l/cbCaidP4vNfPW3oc","pdf",1852176,11,"English","# Abstract\n# Introduction\n# Methods and materials\n# Results\n# Conclusions","[{\"question\":\"What is the main purpose of MRgSMART-PEM in this study?\",\"answer\":\"To evaluate the safety, feasibility, and patient-reported outcomes of magnetic resonance-guided simultaneous multi-focal adaptive radiotherapy for the prostate, pelvis, and metastases in specific high-risk categories of prostate cancer.\"},{\"question\":\"How was the radiotherapy delivered and what was the study design?\",\"answer\":\"This was a prospective single-arm phase II study. Thirty-five patients were treated with MRgSMART-PEM on a 1.5-T MR-Linac between June 2021 and March 2025, delivered in five alternate-day fractions using an Adapt-to-Shape workflow.\"},{\"question\":\"What were the key toxicity and quality-of-life findings?\",\"answer\":\"Acute grade ≥2 GU and GI toxicities occurred in 5.7% of patients each, and all resolved within 8 weeks. No late grade ≥2 toxicities were observed, and quality-of-life scores declined at 2 weeks but returned to baseline by 3 months.\"}]","Magnetic resonance-guided simultaneous multi-focal adaptive radiotherapy for prostate, pElvis & metastases (MRgSMART-PEM) in prostate cancer - a prospective phase II study | PDF",1790055398,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bb36a49485c392725ac1eabd39d4f555.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aad1e2e0a50aa7f7fb65b25801e359c2.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2e7fc5bd1397ed83d80b5409dcb8b7f7.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ca7bfe0a29b066f68a109b82389a8dc9.webp",980,1306]